Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) closed up over 22% on Wednesday at $2.02 trading around 4 million shares by the market close. The company recently reported that it will commence offering personalized CBD anti-tumor tests for people suffering with cancer.

The diagnostic tests use liquid biopsies of cancer patients. The test is based on CTC technology that gathers cancer cells from cancer patients’ blood samples, and examines their sensitivity to cannabinoid compounds administered together with conventional chemotherapy medicine.

The buzz

Cannabinoid products, treatments and therapies continue to advance through R&D breakthroughs, prompting robust forecast for this year performance. Clinical trials in which a combination of Cannabidiol and tetrahydrocannabinol were used to cure patients continue to identify fresh opportunities for cannabis firms.

Medical Marijuana and legalized cannabis firms in the markets with recent advancements and performance of note comprise: Cannabics, Vinergy Resources Ltd (OTC: VNNYF), Canopy Growth Corporation (OTCMKTS:TWMJF) and OWC Pharmaceutical Research Corp (OTCMKTS:OWCP).

Earlier in January, the company reported advancement of its 5mg THC Capsule planned for naïve patient who have not experimented cannabis in the past. Cannabics Chief Scientist, Dr. Eyal Ballan, reported that their objective is to seek the right balance between the removal of undesired psychoactive effects and efficacy.

Their 5mg THC capsule is presently being assessed by the firm in a clinical trial as a palliative treatment, which is performed by the oncology department at the Rambam Medical Center and under stringent guidelines of the Ministry of Health, by whom company has been approved since 2014.

The trial is happening in Israel, and is registered with the US NIH. Itamar Borochov, the CEO of Cannabics Pharmaceuticals, reported that the majority of their cancer trial subjects have no preliminary experience with Cannabis, so this recalibration of the tetrahydrocannabinol level may be increasingly amenable. They consider there is a significant prospective medical market for 5mg THC capsule in nations that have now established medical cannabis regulations.

The following two tabs change content below.

Jaime Williams

Jaime is a MBA graduate from UC San Diego and has written for MMJObserver.com for over 3 months now. She has a particular fondness for the medical marijuana industry but also likes writing on energy, consumer goods, and technology.